EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique

Gregg W Stone, Dean J Kereiakes, Tommaso Gori, D Christopher Metzger, Bernardo Stein, Matthew Erickson, Jan Torzewski, Ameer Kabour, Guy Piegari, Jeffrey Cavendish, Barry Bertolet, Kelly A Stockelman und 7 weitere

Journal of the American College of Cardiology · 2023-07 · 82 (3) · 183-195

DOI: 10.1016/j.jacc.2023.05.003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American College of Cardiology, 2023-07. Verfasst von Gregg W Stone und 18 weiteren Autor:innen. Beteiligte Einrichtung: Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: gregg.ston…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bioresorbable vascular scaffolds (BVS) were designed to improve late event-free survival compared with metallic drug-eluting stents. However, initial trials demonstrated worse early outcomes with BVS, in part due to suboptimal technique. In the large-scale, blinded ABSORB IV trial, polymeric everolimus-eluting BVS implanted with improved technique demonstrated noninferior 1-year outcomes compared with cobalt chromium everolimus-eluting stents (CoCr-EES). OBJECTIVES: This study sought to evaluate the long-term outcomes from the ABSORB IV trial. METHODS: We randomized 2,604 patients at 147 sites with stable or acute coronary syndromes to BVS with improved technique vs CoCr-EES. Patients, clinical assessors, and event adjudicators were blinded to randomization. Five-year follow-up was completed. RESULTS: Target lesion failure at 5 years occurred in 216 (17.5%) patients assigned to BVS and 180 (14.5%) patients assigned to CoCr-EES (P = 0.03). Device thrombosis within 5 years occurred in 21 (1.7%) BVS and 13 (1.1%) CoCr-EES patients (P = 0.15). Event rates were slightly greater with BVS than CoCr-EES through 3-year follow-up and were similar between 3 and 5 years. Angina, also centrally adjudicated, recurred within 5 years in 659 patients (cumulative rate 53.0%) assigned to BVS and 674 (53.3%) patients assigned to CoCr-EES (P = 0.63). CONCLUSIONS: In this large-scale, blinded randomized trial, despite the improved implantation technique, the absolute 5-year rate of target lesion failure was 3% greater after BVS compared with CoCr-EES. The risk period for increased events was limited to 3 years, the time point of complete scaffold bioresorption; event rates were similar thereafter. Angina recurrence after intervention was frequent during 5-year follow-up but was comparable with both devices.(Absorb IV Randomized Controlled Trial; NCT02173379).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseasePercutaneous Coronary InterventionHumansAbsorbable ImplantsEverolimusProsthesis DesignStentsTissue ScaffoldsTreatment Outcome

Stichwörter der Autor:innen

anginabioresorbable scaffoldcoronary artery diseaseprognosisrandomized trialstent

Substanzen

Everolimus

Autor:innen und Institutionen

  • Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: gregg.stone@mountsinai.org.
  • Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, USA.
  • Kardiologie I University Medical Center and DZHK Rhein-Main, Mainz, Germany.
  • Ballad Health Systems CVA Heart Institute, Kingsport, Tennessee, USA.
  • Morton Plant Hospital, Clearwater, Florida, USA.
  • Fiona Stanley Hospital, Perth, Westwern Australia, Australia.

Zitieren

APA

Stone, G. W., Kereiakes, D. J., Gori, T., Metzger, D. C., Stein, B., Erickson, M., Torzewski, J., Kabour, A., Piegari, G., Cavendish, J., Bertolet, B., Stockelman, K. A., West, N. E. J., Ben-Yehuda, O., Choi, J. W., Marx, S. O., Spertus, J. A., Ellis, S. G., & ABSORB IV Investigators (2023). 5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique. Journal of the American College of Cardiology, 82(3), 183-195. https://doi.org/10.1016/j.jacc.2023.05.003

Vancouver

Stone GW, Kereiakes DJ, Gori T, Metzger DC, Stein B, Erickson M, et al. 5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique. Journal of the American College of Cardiology. 2023;82(3):183-195. doi:10.1016/j.jacc.2023.05.003

BibTeX
@article{Stone2023,
  author = {Stone, Gregg W and Kereiakes, Dean J and Gori, Tommaso and Metzger, D Christopher and Stein, Bernardo and Erickson, Matthew and Torzewski, Jan and Kabour, Ameer and Piegari, Guy and Cavendish, Jeffrey and Bertolet, Barry and Stockelman, Kelly A and West, Nick E J and Ben-Yehuda, Ori and Choi, James W and Marx, Steven O and Spertus, John A and Ellis, Stephen G and ABSORB IV Investigators, ABSORB IV Investigators},
  title = {5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique},
  journal = {Journal of the American College of Cardiology},
  year = {2023},
  volume = {82},
  number = {3},
  pages = {183--195},
  doi = {10.1016/j.jacc.2023.05.003}
}
Kostenlos starten →